CSIMarket


Nuvation Bio Inc   (NUVB)
Other Ticker:  
 


 

Nuvation Bio Inc

NUVB's Financial Statements and Analysis



Nuvation Bio Inc narrowed third quarter of 2023 net loss per share of $-0.09 compare to net loss per share of $-0.12 recorded in the same quarter a year ago a decrease compare to $-0.09 realized in previous quarter.


third quarter of 2023
Earnings Per Share Revenues
$ -0.09 $  0 Mill
$+0.03     Unch.    



Nuvation Bio Inc 's Revenue fell by 0 % in third quarter of 2023 (Sep 30 2023) year on year, to $0 million and declined by sequentially.


Nuvation Bio Inc is

More on NUVB's Income Statement



Nuvation Bio Inc 's in thethird quarter of 2023 recorded net loss of $-19.649 million, an improvement compare to net loss of $-27.203 million in III. Quarter a year ago.

Sequentially net loss narrowed from net loss of $-20.640 million realized in previous quarter.

More on NUVB's Growth

Nuvation Bio Inc Inventories
In Sep 30 2023 company's net cash and cash equivalents decreased by $-26 million, capital expenditures grew by -0.103-78.64%, to $0 millions compare to same quarter a year ago

More on NUVB's Cash flow Statement


Nuvation Bio Inc does not pay out common stock dividend.

In trailing twelve-month period Nuvation Bio Inc payed $ -0.32 cash per share, on a free-cash flow basis .

Book value grew by 2.85 % sequentially to $2.80 per share.
Tangible Book value grew to $ 2.80 per share from $ 2.72.

Company repurchased 11.01 million shares or 4.80 % in Sep 30 2023.


More on NUVB's Dividends

 Market Capitalization (Millions) 498
 Shares Outstanding (Millions) 218
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -83
 Cash Flow (TTM) (Millions $) -114
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -




Nuvation Bio Inc does not pay out common stock dividend.

In trailing twelve-month period Nuvation Bio Inc had negative $ -0.32 cash flow per share, on a free-cash flow basis .

Book value grew by 2.85 % sequentially to $2.80 per share.
Tangible Book value grew to $ 2.80 per share from $ 2.72.

Company repurchased 11.01 million shares or 4.80 % in Sep 30 2023.


More on NUVB's Balance Sheets

 Market Capitalization (Millions) 498
 Shares Outstanding (Millions) 218
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -83
 Cash Flow (TTM) (Millions $) -114
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -
   


  News about Nuvation Bio Inc Earnings

NUVB's Financial Report Reveals Encouraging Results for Q3 2023 in Major Pharmaceutical Preparations Sector

In the Major Pharmaceutical Preparations industry, after the performance of large companies, attention is now shifting to the results of smaller companies. Nuvation Bio Inc. (NYSE: NUVB) recently reported its financial results for the third quarter of 2023, which indicates positive news for the company.
NUVB announced an operating loss of -$26.339 million for the third quarter of 2023, which is viewed as good news compared to the operating loss of -$29.338 million in the third quarter of 2022. This improvement in operating loss has generated optimism among most analysts about NUVB's potential. Additionally, the net loss for the company has also shown improvement, with diminishing returns compared to the ...

Nuvation Bio Inc. Shocks Investors with a Soaring Operating Deficit for the Second Quarter of 2023

Financial News Report: Nuvation Bio Inc's Q2 Results Show Improved Performance
In the April to June 30, 2023 reporting cycle, Nuvation Bio Inc did not witness significant changes as expected by the stockholders. However, investors noticed an operating deficit improvement during this period. The company managed to reduce the operating deficit to $-26.131 million, compared to the previous fiscal period ending June 30, 2022, where the deficit stood at $-37.87 million. This signifies that NUVB operated more efficiently in the current reporting cycle.
Despite the ongoing growth in revenue streams, NUVB successfully reduced its deficit further in the financial second quarter of 2023 to $-20.640 million, co...

Breaking News: Nuvation Bio Inc Takes on the Challenges of Fiscal First Quarter 2023

The pharmaceutical industry is a critical component of the global economy, responsible for the development and manufacturing of drugs and other medical treatments that improve public health and wellbeing. Companies in this sector operate in an increasingly competitive and complex environment, often requiring significant investments in research and development to stay ahead of the curve. As with any industry, earnings reports provide valuable insights into the financial health of pharmaceutical companies and their ability to grow and innovate.
One such company is Nuvation Bio Inc (NUVB), a rising organization within the pharmaceutical preparations sector. Insiders in this industry have been closely monito...


Date modified: 2023-11-03T16:02:10+00:00





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com